Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Applied Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Applied Therapeutics Inc.

APLT

Applied Therapeutics Inc.

About Applied Therapeutics Inc.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel aldose reductase inhibitors (ARIs) targeting molecular pathways implicated in rare metabolic and diabetic complications. Its lead product, AT-007, addresses rare pediatric diseases like Galactosemia and SORD Deficiency by reducing toxic sugar metabolites. The company leverages advanced drug design, biomarker-driven development, and accelerated regulatory pathways to create selective therapies for underserved patient populations with high unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Applied Therapeutics Inc.

1
1
Applied Therapeutics Inc. Applied Therapeutics Reports $1 Million Revenue in Q3 2025, Sees Significant Losses and Funding Concerns

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Applied Therapeutics Inc. Applied Therapeutics Reports Zero Revenue and $21.3 Million Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Applied Therapeutics Inc. Applied Therapeutics Reports $21.8 Million Net Loss in Q1 2025, Revenue Drops to $0

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Applied Therapeutics Inc. Applied Therapeutics Reports $105.6 Million Net Loss for 2024, Revenue Declines to $0.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Applied Therapeutics Inc. Applied Therapeutics Reports Significant Cash Increase, Revenue Growth, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments